These effects may be mediated by altering chemokine-induced immune migration into tumors since BRAF inhibition in melanoma increased serum levels of CCL2, CCL4, and decreased CXCL8 (86), which correlated with increased CD8+ T cell infiltration. The gene discussed is BRAF; the disease is melanoma.